Get started

PHARMA

SUNPHARMA - Sun Pharmaceuticals Industries Limited Levels - Buy - Any dip the CMP or it breaks above 628 T1 - 645 T2 - 700 SL - 610 The undertone of the Pharma sector is bullish amid the second wave of COVID-19 hitting India. Sun Pharmaceuticals has the largest market capitalization and is currently trading at half the price of its all-time high which was close to 1200. The stock has seen a major correction from 1200 levels since FY-15 and now might have resumed a pullback. Current scenario - The stock has started trading above all its important exponential moving averages in 5-6 sessions. However the stock has a strong supply zone at the levels of 625-628, so once the stock breaks this level, an upside move up to the levels of 650 followed by 700 looks achievable. A key thing to note here that the stock is trading above all its moving averages and have NOTE: These findings and levels are purely based upon the knowledge and understanding of the post publisher. The idea here is to predict the future price movements hence, please do not consider this as stock advice or recommendation.
NSE:SUNPHARMALong
by mishraparimal09
LXRX - a gain again?Possibility to gain again? It looks like it want to crawl up on a support line (green). I've packed bags here a little. Indicators are almost reversed to bullish. But it still can go lower if it breaks the support line. Remember to have a stop loss below the support line. There is a big gap below 5.60. There also could happen a bear trap, quick fall and then quick retrace and skyrocketing. This one is going to be fun soon. But Reward/Risk ratio is promising. 1st target point is 7.60(+over 30% profit). fundamentally : beating almost every estimations lately. Good luck!
NASDAQ:LXRXLong
by MateuszZakrzewski
ATOS - Triple Bottom with a Breakout?Set up looks great. Triple bottom, break out and retest of a diagonal resistance. I absolutely dislike stocks like this but I like the chart. Will there be a catalyst to move this? The only catalyst for this one is the recent FDA "safe to proceed" letter to continue ovarian cancer treatment. If it actually materializes, could see a run towards levels above. It will only move if it catches momo crowd, otherwise just another garbage stonk.
NASDAQ:ATOSLong
by bossmodetrader
CPRX Catalyst Pharmaceuticals $40M Repurchase P/E Ratio 6.5 WOWCatalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com) The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share. The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com) CPRX it`s an easy 50% in my opinion. $40 Million Share Repurchase. Market Cap 453.715M. PE Ratio (TTM) 6.15. 75mil revenue, 119mil earnings in 2020 haven`t seen such a great balance sheet on a penny stock. now trading at 4,94usd. 3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00 H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9 If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:CPRXLong
by TopgOptions
11
$ACRX to 7$ In December AcelRx published clinical data in „The Journal of Universal Surgery“ titled „A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain“. What is DSUVIA? According to AcelRx DSUVIA is a recently approved drug „indicated for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opiod analgesic.“ The US army recently awarded AcelRX with a ~$3.6M contract in order to purchase for the drug DSUVIA to support a study made by the US army as well as purchases for the stocking of their medical equipment for troop deployment and additional purchases by other branches of the military following the recent approval of DSUVIA. AcelRx estimates that DSUVIA has the potential to reach over $1B in annual revenues. To put that into perspective - in 2019 they posted revenues of only $2.29M. Technical Analysis is currently at a crucial point as price will soon break the symetric triangle in either direction - it will most likely be a movement in the upper direction as the Fibo Levels of the recent upwards trend as well as the $2.00 level act as strong support in combination with the good fundamental data. Most institutional investors also seem to hold a bullish bias according to the data my broker provides.
ALong
by EnisGuriGashi
3
Long #ENLV above 18.50, COVID news#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a longer term position and consider the 10.72-12.32 for a reentry. Based on trend projection confluence and fib levels, id be looking to sell some shares at the 28.00 level If we happen to see price action above these levels, i would consider targeting 37$ down the road. The top of this trading range would be close to $45, Currently trading at 15.49
NASDAQ:ENLVLong
by TradingNomadic